

Amendments to the Claims

This listing of claims will replace all prior version and listings of claims in the application:

Listing of Claims:

1. (Currently amended): A pharmaceutical composition for cancer therapy essentially consisting of comprising as active substances:
 - a) at least one compound having glutaminase activity; ~~and~~
 - b) at least one antineoplastic agent selected from the group consisting of platinum complexes and anthracyclines ~~[[.]]~~; and
 - c) at least one of carrier substances, auxiliary substances, and pharmaceutical injection media.
2. (Previously presented): The composition as claimed in claim 1, characterized in that
the at least one compound having glutaminase activity is a glutaminase, glutaminase-asparaginase, glutaminase analogue, derivative or modification thereof and is either of natural origin or is produced synthetically.
3. (Previously presented): The composition as claimed in claim 2, characterized in that
the at least one compound having glutaminase activity is from Pseudomonas, preferably Pseudomonas 7A glutaminase-asparaginase.

4. (Previously presented): The composition as claimed in claim 1, characterized in that the at least one compound having glutaminase activity is modified with polyethylene glycol.
5. (Previously presented): The composition as claimed in claim 1, characterized in that the anthracyclines comprise at least one of doxorubicin, daunomycin, actinomycin D and mitoxantrone.
6. (Previously presented): The composition as claimed in claim 1, characterized in that the platinum complexes comprise at least one of cis-platinum, oxaliplatin and carboplatin.
7. (Previously presented): A process for producing the pharmaceutical composition as claimed in claim 1, characterized in that the active substances are processed into oral or parenteral forms of administration.
8. (Withdrawn): Use of in particular a compound having glutaminase activity and at least one antineoplastic agent selected from platinum complexes and anthracyclines to produce an agent for an antineoplastic therapy.

9. (Withdrawn): Method for treating cancer and other diseases which are associated with abnormal cell proliferation, characterized in that at least one compound having glutaminase activity and at least one antineoplastic agent selected from platinum complexes or anthracyclines are administered in a molar ratio between 1:10 to 1:1000 and 10:1 to 1000:1, where the doses to be administered daily are 0.005 – 100 mg/kg body weight per individual component.
10. (Previously presented): The process as claimed in claim 7, characterized in that the active substances are mixed together with common pharmaceutical carrier substances or auxiliary substances.